Objetivo Breast cancer is the most common cancer in women worldwide, with nearly 1.7 million new cases diagnosed in 2012. Fortunately, the availability of diagnosis tools to detect mammary neoplastic tissues, as well as transcriptomic biomarkers helping for prognosis, and the diversity of treatment options for primary tumors allows a 90% 5-year survival rate. However the metastatic grade of breast cancer is still not curable.Advances from basic research in the last decade outline the epithelial-to-mesenchymal transition (EMT) as a key program of molecular events triggering metastatic dissemination [Nieto MA, Cell, 2016]. Impairing the EMT process appears as a very seductive way to cure breast carcinoma cancer. Based on preliminary results obtained from “SPICY” ERC Frontier Research Starting Grant, in which we successfully develop an assay dedicated to characterize the EMT state of breast carcinoma cells [Thery M, EP 2180042 A1, 2008 ; Burute M, Dev. Cell, 2016], MATADOR is an ERC proof-of-concept project which proposes a genuine innovative strategy to develop marketable cell based assays allowing the discovery of new drugs efficiently curing mammary tumors, and create a CRO-type biotechnology company exploiting the pre-existing and newly created intellectual property: including marketable assays and therapeutics defined in MATADOR. Ámbito científico medical and health sciencesclinical medicineoncologybreast cancer Programa(s) H2020-EU.1.1. - EXCELLENT SCIENCE - European Research Council (ERC) Main Programme Tema(s) ERC-2017-PoC - ERC-Proof of Concept Convocatoria de propuestas ERC-2017-PoC Consulte otros proyectos de esta convocatoria Régimen de financiación ERC-POC - Proof of Concept Grant Institución de acogida COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES Aportación neta de la UEn € 149 645,00 Dirección RUE LEBLANC 25 75015 PARIS 15 Francia Ver en el mapa Región Ile-de-France Ile-de-France Paris Tipo de actividad Research Organisations Enlaces Contactar con la organización Opens in new window Sitio web Opens in new window Participación en los programas de I+D de la UE Opens in new window Red de colaboración de HORIZON Opens in new window Coste total € 149 645,00 Beneficiarios (1) Ordenar alfabéticamente Ordenar por aportación neta de la UE Ampliar todo Contraer todo COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES Francia Aportación neta de la UEn € 149 645,00 Dirección RUE LEBLANC 25 75015 PARIS 15 Ver en el mapa Región Ile-de-France Ile-de-France Paris Tipo de actividad Research Organisations Enlaces Contactar con la organización Opens in new window Sitio web Opens in new window Participación en los programas de I+D de la UE Opens in new window Red de colaboración de HORIZON Opens in new window Coste total € 149 645,00
